These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 84882)

  • 1. [Clinical application of NK-631, a new bleomycin to head-and-neck malignant tumors (author's transl)].
    Makimoto K; Nagahara K
    Jpn J Antibiot; 1979 Jan; 32(1):121-8. PubMed ID: 84882
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical experiences with pepleomycin (NK 631) (author's transl)].
    Kusakari J; Sato Y; Saijo S; Tomioka S; Kawamoto K
    Jpn J Antibiot; 1978 Nov; 31(11):659-63. PubMed ID: 83402
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical application of NK 631 to head-and-neck cancers (author's transl)].
    Ogawa Y; Omata T; Imaizumi H; Shiga H; Ouchi J
    Jpn J Antibiot; 1979 Jan; 32(1):115-20. PubMed ID: 84881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary effect of NK 631 against head-and-neck cancers (author's transl)].
    Takata K; Honda T
    Jpn J Antibiot; 1979 Jan; 32(1):106-14. PubMed ID: 84880
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical effects of NK 631 (pepleomycin) against malignant tumors of the head and neck (author's transl)].
    Satoh F; Saitoh H; Mizukoshi O
    Jpn J Antibiot; 1979 Jul; 32(7):751-5. PubMed ID: 90743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].
    Kawahira K; Dohhara Y; Sugihara K; Yamada K; Fujinami Y; Saku T; Yamashita S
    Jpn J Antibiot; 1979 Jan; 32(1):138-48. PubMed ID: 84884
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment with NK 631 (new bleomycin analog) of oral and maxillofacial cancer (author's transl)].
    Nakanishi K; Miki T; Adachi K; Teranobu O; Shimada K
    Jpn J Antibiot; 1979 Feb; 32(2):282-90. PubMed ID: 86625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with NK 631 in malignant tumors of skin (author's transl)].
    Nobe O; Kubo H; Yoshii K; Tashiro M
    Jpn J Antibiot; 1979 Mar; 32(3):463-9. PubMed ID: 86628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Histological appearances of cancer of the head and neck treated with pepleomycin (NK 631) (author's transl)].
    Matsumura Y; Nomura Y; Eguchi S; Yanagita T
    Jpn J Antibiot; 1978 Nov; 31(11):651-8. PubMed ID: 83401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with pepleomycin (NK 631) (author's transl)].
    Hashimoto K; Shioda S; Amagasa T; Shimizu M; Sato O; Ito H; Fujibayashi T; Soda T
    Jpn J Antibiot; 1979 Mar; 32(3):451-62. PubMed ID: 86627
    [No Abstract]   [Full Text] [Related]  

  • 11. [Results of bleomycin therapy in recurrent head and neck tumors (author's transl)].
    Ritter R; Ganzer U
    HNO; 1976 Jan; 24(1):14-6. PubMed ID: 60326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].
    Kajiyama M; Dohjyo M; Ohno A; Nagasaka K; Yamaguma M; Okabe T; Terasaka S
    Jpn J Antibiot; 1979 Jan; 32(1):129-37. PubMed ID: 84883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preoperative application of NK 631 for carcinoma of oral cavity (author's transl)].
    Yamamoto E; Sunakawa H; Kohama GI
    Jpn J Antibiot; 1979 Feb; 32(2):253-8. PubMed ID: 86621
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical experience with NK 631 (pepleomycin) for malignant tumors of skin (author's transl)].
    Seki T; Shimada S; Ohara K
    Jpn J Antibiot; 1979 Feb; 32(2):278-81. PubMed ID: 86624
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical application of NK 631, a new derivative of bleomycin (author's transl)].
    Asahi M
    Jpn J Antibiot; 1979 Jul; 32(7):744-50. PubMed ID: 90742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on the clinical effect of NK 631 for oral-cavity cancers (author's transl)].
    Ohashi Y; Abe M; Saito K; Mizutani H; Onishi S; Ueda N
    Jpn J Antibiot; 1979 Feb; 32(2):259-64. PubMed ID: 86622
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experience with bleomycin in head and neck tumors].
    Meijer NC; Snow GB
    Ned Tijdschr Geneeskd; 1976 Feb; 120(6):237-40. PubMed ID: 55980
    [No Abstract]   [Full Text] [Related]  

  • 18. [Randomized trial of vincristin-methotrexate-bleomycin and cis-platin or detorubicin for advanced head and neck cancer (author's transl)].
    Cappelaere P; Chauvergne J; Klein T; Gary-Bobo J; Guerrin J; Meeus L
    Bull Cancer; 1981; 68(5):422-7. PubMed ID: 6174165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I and phase II studies of a new bleomycin (pepleomycin) (author's transl)].
    Miura T; Katayama K; Wada T
    Jpn J Antibiot; 1979 Feb; 32(2):265-77. PubMed ID: 86623
    [No Abstract]   [Full Text] [Related]  

  • 20. [Application of BLM-iontophoresis for the tumor-therapy of the head and neck area (author's transl)].
    Hayasaki K; Kitamura T; Kaneko T; Tachibana M; Kobayashi N; Tosaka K; Yaku Y
    Nihon Gan Chiryo Gakkai Shi; 1977 Dec; 12(4):522-7. PubMed ID: 75935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.